<SEC-DOCUMENT>0001193125-21-162869.txt : 20210517
<SEC-HEADER>0001193125-21-162869.hdr.sgml : 20210517
<ACCEPTANCE-DATETIME>20210517083028
ACCESSION NUMBER:		0001193125-21-162869
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210517
DATE AS OF CHANGE:		20210517

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMARIN PHARMACEUTICAL INC
		CENTRAL INDEX KEY:			0001048477
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				680397820
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26727
		FILM NUMBER:		21927751

	BUSINESS ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
		BUSINESS PHONE:		4155066700

	MAIL ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d167672ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 (Amendment No. ) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9746;&nbsp;&nbsp;Filed by the
Registrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Filed by a Party other than the Registrant</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CHECK THE APPROPRIATE BOX: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, For Use of the Commission Only (as permitted by Rule <FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Under Rule <FONT STYLE="white-space:nowrap">14a-12</FONT></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g167672dsp2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>BioMarin Pharmaceutical Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the form or schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount previously paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g167672dsp2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOMARIN PHARMACEUTICAL INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUPPLEMENT TO THE PROXY STATEMENT FOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE 2021 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON MAY&nbsp;25, 2021 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the
2021 Annual Meeting of Stockholders (the Annual Meeting) of BioMarin Pharmaceutical Inc., a Delaware corporation (we, us, BioMarin or the Company) to be held virtually on May&nbsp;25, 2021 at 9:00 a.m. (Pacific Time), our stockholders are being
asked, among other things, to vote to <FONT STYLE="white-space:nowrap">re-elect</FONT> our current directors to serve until the 2022 Annual Meeting of Stockholders (Proposal 1 in BioMarin&#146;s definitive proxy statement on Schedule 14A filed with
the Securities and Exchange Commission on April&nbsp;13, 2021 (the Proxy Statement)) and approve, on an advisory basis, the compensation of the Company&#146;s Named Executive Officers (NEOs) as disclosed in the Proxy Statement (Proposal 3 in the
Proxy Statement). We are providing this Supplement to the Proxy Statement as additional information and context to help our stockholders evaluate Proposals 1 and 3 in the Proxy Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proposal 1 &#150; Election of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of
Directors (Board) has recommended that stockholders vote for the <FONT STYLE="white-space:nowrap">re-election</FONT> of all our current directors, including Michael Grey, a member of our Board since 2005 who serves as the Chair of our Compensation
Committee and as a member of our Science&nbsp;&amp; Technology Committee. Mr.&nbsp;Grey currently serves as a director at six public companies (including BioMarin), including one that became public in October 2020 as a result of an initial public
offering (IPO) and one that became public in April 2021 as a result of an IPO. Mr.&nbsp;Grey understands that as a result of these recent IPOs, he serves on more boards of directors than is recommended in BioMarin&#146;s Corporate Governance
Principles and is considered &#147;overboarded&#148; by the proxy voting guidelines of certain of our investors and certain proxy advisory firms. In order to align his commitments with the recommendations of the Company&#146;s Corporate Governance
Principles and address investor concerns, Mr.&nbsp;Grey has committed to reduce the number of public company boards on which he serves to no more than five by the end of the third quarter of 2021. We believe that Mr.&nbsp;Grey is able to continue to
devote sufficient time to fulfill his duties to BioMarin and that he has been, and will continue to be, an effective and engaged director who has beneficial experience, perspective, and skills, and that
<FONT STYLE="white-space:nowrap">re-electing</FONT> him to the Board will enhance long-term stockholder value creation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Board
strongly recommends a vote &#147;FOR&#148; Mr.&nbsp;Grey under Proposal 1. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proposal 3 &#150; Advisory Vote on Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board has recommended that stockholders vote for the approval, on a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory basis, of the compensation
of the Company&#146;s NEOs as disclosed in the Proxy Statement. As previously disclosed, Daniel&nbsp;Spiegelman, the Company&#146;s former Executive Vice President and Chief Financial Officer and former NEO, was paid severance pursuant to his
Amended and Restated Employment Agreement dated June&nbsp;10, 2015 (the Employment Agreement). After the Company filed its Proxy Statement, proxy advisory firm Institutional Shareholder Services (ISS) recommended a vote &#147;AGAINST&#148; Proposal
3. ISS stated the reason for its &#147;AGAINST&#148; vote recommendation was &#147;in light of insufficient disclosure provided regarding separation arrangements made for former NEO Daniel Spiegelman&#148;; however, ISS noted that <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;pay-for-performance</FONT></FONT> concerns were sufficiently mitigated for the year in review.&#148; Specifically, ISS stated that &#147;[a]lthough the [C]ompany states that he was
entitled to severance payments pursuant to his employment agreement, it does not distinctly define how it treated the separation, and it is not clear whether [Mr.] Spiegelman resigned or his employment was terminated by the [C]ompany.&#148; We are
providing the following information to clarify circumstances surrounding Mr.&nbsp;Spiegelman&#146;s separation of employment from the Company and related severance payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In early 2020, our Board asked Mr.&nbsp;Spiegelman to step down as Chief Financial Officer of the Company, while the Board continued to recognize the
important contributions and leadership Mr. Spiegelman demonstrated during his tenure. Under the terms of the Employment Agreement, such request constituted a &#147;termination without Cause&#148; and triggered the Company&#146;s obligation to make
the severance payment to Mr.&nbsp;Spiegelman pursuant to Section&nbsp;6(d)(i), &#147;Employment Termination Without Cause; Resignation For Good Reason &#150; Termination Not in Connection with a Change in Control.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Board strongly recommends a vote &#147;FOR&#148; Proposal 3. </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g167672dsp2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g167672dsp2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  V 58# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z]_X*A_\
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MTGBZ6*]JHZN,HI7774^[[2[BO[6.>&1)H9D#QNC!ED4C((/<$5PO[3'QEF^
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M-\)O#O@WP];+::-X:L(M/M8PH!*HH&YL=78Y9CW9B3R:_'[]N _\(S_P<6^
M;O4B+>TNM>\-2022'*LI\F('V'F*1D],$].:_:FOH>*6Z>"P.&AI#V:E\Y;L
M_G7AA*IB<9B9_$ZCC\EL@HHHKXL^P"OB[_@N[^S#:?M!?L$>(=72TCDU[X=J
M?$-A/M^>.*/'VI,]=A@WL1T+1(3]T5]HUY#^W]J=EI'[#?Q@GU ;K,>#-665
M,X\P&SE78/=LX'/>O5R+$5*&8T*M+=27YVM\T>5GE"%;+ZU.IMRO\%='S9_P
M;O\ QXN/BY^P'%H=_.TUW\/]8N-%C+L6<VK!+B')]%\YXU'98@.U;G_!P)_R
MC)\8?]?VF_\ I=!7A?\ P:\65U'\#/BE<L3]BEUVUBB&S_EHMN2_S=^'CX[?
MC7NG_!P'_P HR?&'_7]IO_I=!7U'L84N+?9T]E5_4^<E5G5X7YY[^S1F_P#!
M(GX+>&OVA?\ @B[X$\(>+])MM:T#6HM7ANK:<<$?VO>$,I'*NI 964@JP!!!
M%?"7Q+^&GQ9_X-]OVLH?%'A::Z\2?"WQ).( 9SMMM6@!+?8[O:,17<8W&.4#
MGEE!!EB'Z,?\$'_^45/PN^NK?^G>]KZ+^/'P(\,?M*_"C6/!7C#38M5T#7(?
M)N(')!!!#*ZL.5=& 96'(*@CI7-A\^^I8_$8;$QY\/.4N:/SW79HZ*^2?6\%
M0Q&'?)7A%<LOEL^Z9\Q_%;_@M[\'?!G['%E\4]'U-=9O];5[;3/#0E6/4C?*
MH+P3KSY2Q[E+R'*[64KOWH&_/W]BS]BWXC_\%K?VCKWXO?%^]OH/ $%SY<LL
M8:%;X(QVZ=8+_! F2'D'3+<M(S,.Y^%7_!MKKL'[8MY8^*=76X^#6ELE[;ZC
M#,J7^M1LQVV913F)QMQ))@#:04Y;Y/U_\#^"-(^&OA#3M T'3K32-%TFW2UL
MK*UC$<-M$HPJJHZ"N_&9GEV3494<DESU*F]1[QB]HKS[O^EQX3+L?FU6-;.(
M\E.&T.DFOM/R[?Y;_GY_P<*^"-(^&O\ P3/\/:!H&G6FD:+I'B2PM;*SM8Q'
M#;1+!<!551T KZ-_X)'?\HV_A!_V 8__ $-Z\(_X.3?^4?VG_P#8V67_ *)N
M*]W_ ."1W_*-OX0?]@&/_P!#>O,QS;X=P[?_ #\G^AW8%)9_B$OY('T;7F/[
M8W[1FG_LF?LS^,/B!J.QD\.Z>\]O"YP+JY8A((<_[<K(GMNKTTU^/W_!S!^U
MS]MU7PI\&-*NLQVH'B'70C=78,EK"WT'FR%3_>B->?PQE#S+,J>&:]W>7^%;
M_?M\ST.),T6 R^=9/WGHO5_Y;A_P;G_LXZA\7?C/X]_:#\6B2_O$N9[#3KN=
M?FN=0N3YM[< X^\$=4R.OVB0=JX/_@IMX1U'_@E]_P %:_#7QG\.VSKH7BB]
M_P"$A\J+"B>0D1ZI:]>LBR%\GC-U_LU[W^P__P %BOV8OV//V6/!WP^M-1\3
MM-HEBOV^>/0Y,75[)F2XDSU(,K-MSR%"CM7F/_!7/_@IQ^SS^WK^RK-H&B7_
M (A7Q?HE[%J>AR7&CR1H9!\DL3/GA7B9^O&Y4/:OOL)'-*^>5)XG#35"JG!^
MZ[*.T?NT_$^'Q<LNHY/3CAZ\'6I-37O*[E]I?,_7WP7XOT_X@^#])U[2;F.\
MTK6[.&_LKB,Y6>&5!)&X]BK CZUJ5^=O_!N=^UQ_PN7]E*]^'.IW!DUSX:7
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MOQU_X(H_\IJ?C_\ ]@_Q%_Z?;.HX=DXY1F$HNS4:?_I1KGT5+-,#&2NFY_\
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M#"^_^/5]1 Y%!-?-_P!O9G_T$U/_  .7^9]'_8N7?\^(?^ Q_P C\,M%MO\
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M6&;S8U=5^9E88P[<8]*ZO]G_ ."&C_LW?!KP]X%\/O>R:+X:M!9VC7<@DG*
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K./F5ES]P9**TIUJE-.,'925GYK>WX&=2C";C*:NXNZ\GL>N4445F:'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
